Adma Biologics (ADMA) Ascends While Market Falls: Some Facts to Note

Adma Biologics (ADMA) closed at $16.47 in the latest trading session, marking a +1.98% move from the prior day. This move outpaced the S&P 500's daily loss of 0.76%. On the other hand, the Dow registered a loss of 0.28%, and the technology-centric Nasdaq decreased by 1.2%.Shares of the infectious disease drug developer have depreciated by 12.42% over the course of the past month, underperforming the Medical sector's gain of 8.26% and the S&P 500's gain of 2.71%.Investors will be eagerly watching for the performance of Adma Biologics in its upcoming earnings disclosure. The company is expected to report EPS of $0.15, up 275% from the prior-year quarter. Meanwhile, our latest consensus estimate is calling for revenue of $112.2 million, up 51.83% from the prior-year quarter.It is also important to note the recent changes to analyst estimates for Adma Biologics. These latest adjustments often mirror the shifting dynamics of short-term business patterns. Therefore, positive revisions in estimates convey analysts' confidence in the company's business performance and profit potential.Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has shifted 11.61% downward. Right now, Adma Biologics possesses a Zacks Rank of #3 (Hold).With respect to valuation, Adma Biologics is currently being traded at a Forward P/E ratio of 23.58. Its industry sports an average Forward P/E of 22.03, so one might conclude that Adma Biologics is trading at a premium comparatively.The Medical - Biomedical and Genetics industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 68, placing it within the top 28% of over 250 industries.The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions.Only $1 to See All Zacks' Buys and SellsWe're not kidding.Several years ago, we shocked our members by offering them 30-day access to all our picks for the total sum of only $1. No obligation to spend another cent.Thousands have taken advantage of this opportunity. Thousands did not - they thought there must be a catch. Yes, we do have a reason. We want you to get acquainted with our portfolio services like Surprise Trader, Stocks Under $10, Technology Innovators,and more, that closed 228 positions with double- and triple-digit gains in 2023 alone.See Stocks Now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report ADMA Biologics Inc (ADMA): Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks